Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Thomas Stephen Basil Insider Profile
4 Followers
Thomas Stephen Basil, Director at Eliem Therapeutics, holds 103.91K shares in Eliem Therapeutics (Ticker: ELYM).
Thomas Stephen Basil has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Thomas Stephen Basil's holdings
Insider Roles
Director
Roles that Thomas Stephen Basil holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Thomas Stephen Basil
Thomas Stephen Basil's Trading History
List of latest transactions for each holding click on a transaction to see Thomas Stephen Basil's performance on stock
You May Also Like
Thomas Stephen Basil insider profile FAQ
What is the percentage of profitable transactions made by Thomas Stephen Basil?
The percentage of profitable transactions made by Thomas Stephen Basil is ―.
What is the average return per transaction made by Thomas Stephen Basil?
The average return per transaction made by Thomas Stephen Basil is ―.
What stocks does Thomas Stephen Basil hold?
Thomas Stephen Basil holds: ELYM stocks.
What was Thomas Stephen Basil’s latest transaction?
Thomas Stephen Basil latest transaction was an Uninformative Buy of ―.
What was Thomas Stephen Basil's most profitable transaction?
Thomas Stephen Basil’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Thomas Stephen Basil's role in Eliem Therapeutics?
Thomas Stephen Basil's role in Eliem Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.